Foundation Medicine Announces Presentations at ASCO

--Data Supports Comprehensive Genomic Profiling for Identifying Therapeutic Treatment Options and Determining Predictors of Therapeutic Response Across Broad Cancer Types--

CAMBRIDGE, Mass. & CHICAGO--(BUSINESS WIRE)-- Foundation Medicine, Inc. (NASDAQ: FMI) today announced that the company and its collaborators will have two oral presentations, six poster discussions and nineteen posters presented at the American Society of Clinical Oncology (ASCO) Annual Meeting 2016 taking place June 3-7 in Chicago.

The schedule for oral presentations by Foundation Medicine and/or its collaborators is as follows:

Date and Time: Sunday, June 5, 2015 from 9:57 - 10:09 a.m. CTTitle: PD-L1 Expression, Cancer Genome Atlas (TCGA) Subtype and Mutational Load are Independent Predictors of Response to Atezolizumab (atezo) in Metastatic Urothelial Carcinoma (mUC; IMvigor210)Abstract Number: 104Location: Hall D1Session: Immunotherapy: Now We’re Getting Personal – Using Genomics and Biomarkers to Predict ResponseSession Type: Clinical Science SymposiumPresenter: Jonathan E. Rosenberg, M.D., medical oncologist, Memorial Sloan Kettering Cancer CenterCollaborator(s): Memorial Sloan Kettering Cancer Center

Date and Time: Sunday, June 5, 2016 from 10:21 - 10:33 a.m. CTTitle: Hybrid Capture-Based Next-Generation Sequencing (HC NGS) in Melanoma to Identify Markers of Response to Anti-PD-1/PD-L1Abstract Number: 105Location: Hall D1Session: Immunotherapy: Now We’re Getting Personal – Using Genomics and Biomarkers to Predict ResponseSession Type: Clinical Science SymposiumPresenter: Douglas Buckner Johnson, M.D., M.S.C.I., clinical director, melanoma, Vanderbilt-Ingram Cancer CenterCollaborator(s): Vanderbilt University

The schedule for poster discussions by Foundation Medicine and/or its collaborators is as follows:

Date and Time: Saturday, June 4, 2016 from 8:00 - 11:30 a.m. CTDiscussion Time: 3:00 – 4:15 p.m. CTTitle: Genomic Profiling to Distinguish Poorly Differentiated Neuroendocrine Carcinomas Arising in Different SitesAbstract Number: 4020Poster Board Number: 12Poster Display Location: Hall ADiscussion Location: Hall D1Session: Gastrointestinal (Noncolorectal) CancerPresenter: Emily K. Bergsland, M.D., endowed chair in medical oncology, University of California San FranciscoCollaborator(s): University of California San Francisco, Helen Diller Family Comprehensive Cancer Center

Date and Time: Saturday, June 4, 2016 from 8:00 – 11:30 a.m. CTDiscussion Time: 3:00 – 4:15 p.m. CTTitle: Total Mutation Burden (TMB) in Lung Cancer (LC) and Relationship with Response to PD-1/PD-L1 Targeted TherapiesAbstract Number: 9017Poster Board Number: 340Poster Display Location: Hall ADiscussion Location: E354bSession: Lung Cancer – Non-Small Cell MetastaticPresenter: David R. Spigel, M.D., chief scientific officer; director, lung cancer research program; principal investigator, Sarah Cannon Research InstituteCollaborator(s): Sarah Cannon Research Institute

Date and Time: Saturday, June 4, 2016 from 8:00 – 11:30 a.m. CTDiscussion Time: 3:00 – 4:15 p.m. CTTitle: Comprehensive Genomic Profiling of 298 Lung Cancers of Varying Histologies Harboring MET Exon 14 AlterationsAbstract Number: 9021Poster Board Number: 344Poster Display Location: Hall ADiscussion Location: E354bSession: Lung Cancer – Non-Small Cell MetastaticPresenter: Sai-Hong Ignatius Ou, M.D., Ph.D., medical oncologist, Chao Family Comprehensive Cancer Center, University of California IrvineCollaborator(s): Chao Family Comprehensive Cancer Center, University of California Irvine

Date and Time: Saturday, June 4, 2016 from 1:00 - 4:30 p.m. CTDiscussion Time: 4:45 – 6:00 p.m. CTTitle: Comprehensive Genomic Sequencing (CGS) of 90 Patient Samples of Anaplastic Thyroid Cancer (ATC)Abstract Number: 6014Poster Board Number: 336Poster Display Location: Hall ADiscussion Location: S406Session: Head and Neck CancerPresenter: Saad A. Khan, M.D., medical oncologist, The University of Texas Southwestern Medical CenterCollaborator(s): The University of Texas Southwestern Medical Center

Date and Time: Monday, June 6, 2016 from 8:00 – 11:30 a.m. CTDiscussion Time: 1:15 – 2:30 p.m. CTTitle: Evaluation of Microsatellite Instability (MSI) Status in 11,573 Diverse Solid Tumors using Comprehensive Genomic Profiling (CGP)Abstract Number: 1523Poster Board Number: 346Poster Display Location: Hall ADiscussion Location: S404Session: Cancer Prevention, Hereditary Genetics and EpidemiologyPresenter: Michael J. Hall, M.D., M.S., associate professor; director, gastrointestinal risk assessment, Fox Chase Cancer CenterCollaborator(s): Fox Chase Cancer Center

Date and Time: Monday, June 6, 2016 from 1:00 – 4:30 p.m. CTDiscussion Time: 4:45 – 6:00 p.m. CTTitle: DNA-Based Genomic Profiling for Classification of Tissue of Origin for Patients with Carcinoma of Unknown Primary SiteAbstract Number: 11519Poster Board Number: 216Poster Display Location: Hall ADiscussion Location: S406Session: Tumor BiologyPresenter: Michael Goldberg, clinical data analyst II cancer genomics, Foundation Medicine

The schedule for poster presentations by Foundation Medicine and/or its collaborators is as follows:

Date and Time: Saturday, June 4, 2016 from 8:00 - 11:30 a.m. CTTitle: Tumor Mutational Burden as a Potential Biomarker for PD-11/PD-L1 Therapy in Colorectal CancerAbstract Number: 3587Poster Board Number: 284Poster Display Location: Hall ASession: Gastrointestinal (Colorectal) CancersPresenter: Thomas J. George, M.D., F.A.C.P., medical director, gastrointestinal oncology, University of FloridaCollaborator(s): University of Florida

Date and Time: Saturday, June 4, 2016 from 8:00 - 11:30 a.m. CTTitle: Genomic Distinctions Between Colon and Rectal Cancer in Young PatientsAbstract Number: 3574Poster Board Number: 271Poster Display Location: Hall ASession: Gastrointestinal (Colorectal) CancerPresenter: Joshua E. Meyer, M.D., assistant professor; residency/fellowship training director, department of radiation oncology, Fox Chase Cancer CenterCollaborator(s): Fox Chase Cancer Center

Date and Time: Saturday, June 4, 2016 from 8:00 - 11:30 a.m. CTTitle: MDM2 Amplification (Amp) to Mediate Cabozantinib Resistance in Patients (Pts) with Advanced RET-Rearranged Lung CancersAbstract Number: 9068Poster Board Number: 391Poster Display Location: Hall ASession: Lung Cancer – Non-Small cell MetastaticPresenter: Romel Somwar, Ph.D., senior research scientist, pathology, Memorial Sloan Kettering Cancer CenterCollaborator(s): Memorial Sloan Kettering Cancer Center

Date and Time: Saturday, June 4, 2016 from 8:00 - 11:30 a.m. CTTitle: Lung-MAP (S1400) Lung Cancer Master Protocol: Accrual, Demographics, and Molecular MarkersAbstract Number: 9088Poster Board Number: 411Poster Display Location: Hall ASession: Lung Cancer - Non-Small Cell MetastaticPresenter: Vassiliki Papadimitrakopoulou, M.D., professor, department of thoracic/head and neck medical oncology, medical oncology, The University of Texas MD Anderson Cancer CenterCollaborator(s): The University of Texas MD Anderson Cancer Center

Date and Time: Saturday, June 4, 2016 from 8:00 - 11:30 a.m. CTTitle: Emerging genomic landscape and therapeutic targets in young patients with colorectal cancer (CRC).Abstract Number: 3589Poster Board Number: 286Poster Display Location: Hall ASession: Gastrointestinal (Colorectal) CancerPresenter: Christopher Hanyoung Lieu, M.D., director, Colorectal Medical Oncology Program, deputy director, Cancer Clinical Trials Office, University of ColoradoCollaborator(s): University of Colorado

Date and Time: Saturday, June 4, 2016 from 8:00 - 11:30 a.m. CTTitle: Significant Systematic and CNS Activity of the RET Inhibitor Vandetanib Combined with mTOR inhibitor Everolimus in Patients with Advanced NSCLC with RET fusionAbstract Number: 9069Poster Board Number: 392Poster Display Location: Hall ASession: Lung Cancer - Non-Small Cell MetastaticPresenter: Tina Cascone, M.D., Ph.D., hematology/oncology fellow, The University of Texas MD Anderson Cancer CenterCollaborator(s): The University of Texas MD Anderson Cancer Center

Date and Time: Saturday, June 4, 2016 from 1:00 - 4:30 p.m. CTTitle: TMPRSS-ERG Fusion in Men with Prostate cancer(PCa) and Non-prostate Malignancies: Defining a role for Comprehensive Genomic Profiling (CGP) to guide Clinical CareAbstract Number: 5037Poster Board Number: 294Poster Display Location: Hall ASession: Genitourinary (Prostate) CancerPresenter: Primo Lara, M.D., associate director for translational research, University of California, DavisCollaborator(s): University of California, Davis

Date and Time: Saturday, June 4, 2016 from 1:00 - 4:30 p.m. CTTitle: Analysis of Tumor Mutational Burden (TMB) in >51,000 Clinical Cancer Patients to identify Novel Non-Coding PMS2 Promoter Mutations Associated with increased TMBAbstract Number: 9572Poster Board Number: 177Poster Display Location: Hall ASession: Melanoma/Skin CancersPresenter: Zachary Rockow Chalmers, senior research associate, Foundation Medicine

Date and Time: Saturday, June 4, 2016 from 1:00 - 4:30 p.m. CTTitle: Comprehensive Genomic Profiling of Neuroendocrine Carcinoma of the ProstateAbstract Number: 5027Poster Board Number: 284Poster Display Location: Hall ASession: Genitourinary (Prostate) cancerPresenter: Philip J. Stephens, Ph.D., chief scientific officer, Foundation Medicine

Date and Time: Saturday, June 4, 2016 from 1:00 - 4:30 p.m. CTTitle: Deep Sequencing of Metastatic Cutaneous Basal Cell and Squamous Cell Carcinomas to Reveal Distinctive Genomic Profiles and New Routes to Targeted TherapiesAbstract Number: 9522Poster Board Number: 127Poster Display Location: Hall ASession: Melanoma/Skin CancersPresenter: Jeffrey S. Ross, M.D., medical director, Foundation MedicineCollaborator(s): Albany College of Medicine

Date and Time: Saturday, June 4, 2016 from 8:00 - 11:30 a.m. CTTitle: The Genomics of Young Lung CancerAbstract Number: 9083Poster Board Number: 406Poster Display Location: Hall ASession: Lung Cancer - Non-Small Cell MetastaticPresenter: Barbara J. Gitlitz, M.D., associate professor of clinical medicine, University of Southern California Keck School of MedicineCollaborator(s): University of Southern California Keck School of Medicine

Date and Time: Sunday, June 5, 2016 from 8:00 - 11:30 a.m. CTTitle: Biomarkers of Immune Checkpoint Inhibitor Response in Metastatic Breast Cancer: PD-L1 Protein Expression, CD274 Gene Amplification, and Total Mutational BurdenAbstract Number: 3057Poster Board Number: 379Poster Display Location: Hall ASession: Developmental Therapeutics and Translational ResearchPresenter: Jeffrey S. Ross, M.D., medical director, Foundation MedicineCollaborator(s): Albany College of Medicine

Date and Time: Monday, June 6, 2016 from 8:00 - 11:30 a.m. CTTitle: Distinct Age-Associated Genomic Profiles Identified in Acute Myeloid Leukemia (AML) Using FoundationOne HemeAbstract Number: 7041Poster Board Number: 33Poster Display Location: Hall ASession: Hematologic Malignancies – Leukemia, Myelodysplastic Syndromes, and AllotransplantPresenter: Katherine Tarlock, M.D., acting instructor, hematology-oncology, Seattle Children’s HospitalCollaborator(s): Fred Hutchinson Cancer Research Center

Date and Time: Monday, June 6, 2016 from 1:00 - 4:30 p.m. CTTitle: Comparison of Upper Tract Urothelial Carcinoma and Urothelial Carcinoma of the Bladder to Reveal Key Differences in Mutational Profile and LoadAbstract Number: 4522Poster Board Number: 145Poster Display Location: Hall ASession: Genitourinary (Nonprostate) CancerPresenter: Sumanta K. Pal, M.D., assistant clinical professor, department of medical oncology & therapeutics research, City of HopeCollaborator(s): City of Hope

Date and Time: Monday, June 6, 2016 from 1:00 - 4:30 p.m. CTTitle: Assessment of Tumor Mutation Burden from >60,000 Clinical Cancer Patients Using Comprehensive Genomic ProfilingAbstract Number: 11558Poster Board Number: 255Poster Display Location: Hall ASession: Tumor BiologyPresenter: Garrett Michael Frampton, Ph.D., associate director, bioinformatics, Foundation Medicine

Date and Time: Monday, June 6, 2016 from 1:00 – 4:30 p.m. CTTitle: Immunotherapy (IO) Versus Targeted Therapy Triage in Advanced Endometrial Adenocarcinoma (aEA) by Coordinate Assessment Tumor Mutation Burden (TMB), Microsatellite Instability (MSI) Status, and Targetable Genomic Alterations (GA)Abstract Number: 5591Poster Board Number: 414Poster Display Location: Hall ASession: Gynecologic CancerPresenter: Alessandro Santin, M.D., professor of obstetrics, gynecology and reproductive sciences; clinical research program leader, gynecologic oncology program, Yale School of MedicineCollaborator(s): Yale School of Medicine

Date and Time: Monday, June 6, 2016 from 1:00 – 4:30 p.m. CTTitle: Comprehensive Genomic Profiling to Identify Clinically Relevant Genomic Alterations in Patients with Advanced Penile CancersAbstract Number: 4573Poster Board Number: 195Poster Display Location: Hall ASession: Genitourinary (Nonprostate) CancerPresenter: Andre Poisl Fay, M.D.Collaborator(s): Pontifícia Universidade Católica do Rio Grande do Sul School of Medicine

Date and Time: Monday, June 6, 2016 from 1:00 – 4:30 p.m. CTTitle: Decision Impact Analysis of Comprehensive Genomic Profiling (CGP) in Advanced Breast Cancer: A Prospective StudyAbstract Number: 11578Poster Board Number: 275Poster Display Location: Hall ASession: Tumor BiologyPresenter: Raquel E. Reinbolt, M.D., assistant professor, internal medicine, college of medicine, The Ohio State UniversityCollaborator(s): The Ohio State University Medical Center James Comprehensive Cancer Center

Date and Time: Monday, June 6, 2016 from 1:00 – 4:30 p.m. CTTitle: Investigating the Utility of Comprehensive Genomic Profiling for Patients with Newly Diagnosed Breast CancerAbstract Number: TPS11617Poster Board Number: 312bPoster Display Location: Hall ASession: Tumor BiologyPresenter: Casey B. Williams, Pharm.D., BCOP, director, molecular and experimental medicine, Avera HealthCollaborator(s): Avera Cancer Institute

About Foundation Medicine

Foundation Medicine (NASDAQ: FMI) is a molecular information company dedicated to a transformation in cancer care in which treatment is informed by a deep understanding of the genomic changes that contribute to each patient’s unique cancer. The company offers a full suite of comprehensive genomic profiling assays to identify the molecular alterations in a patient’s cancer and match them with relevant targeted therapies, immunotherapies and clinical trials. Foundation Medicine's molecular information platform aims to improve day-to-day care for patients by serving the needs of clinicians, academic researchers and drug developers to help advance the science of molecular medicine in cancer. For more information, please visit http://www.FoundationMedicine.com or follow Foundation Medicine on Twitter (@FoundationATCG).

Foundation Medicine® and FoundationOne® are registered trademarks, and FoundationACT™ is a trademark of Foundation Medicine, Inc.

Cautionary Note Regarding Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the ability of comprehensive genomic profiling, including FoundationOne, FoundationOne Heme and FoundationACT to identify genomic alterations, identify relevant therapies and improve patient outcomes; and the clinical relevance of comprehensive genomic profiling in cancer treatment and the development of targeted therapies. All such forward-looking statements are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include the risk that the results presented are found to lack scientific, medical or clinical utility or that subsequent research renders the results presented less useful or not useful in clinical practice; Foundation Medicine's services and molecular information platform will not be able to identify genomic alterations in the same manner as prior clinical data; and the risks described under the caption "Risk Factors" in Foundation Medicine's Annual Report on Form 10-K for the year ended December 31, 2015, which is on file with the Securities and Exchange Commission, as well as other risks detailed in subsequent filings with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and Foundation Medicine undertakes no duty to update this information unless required by law.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160518006547/en/

Media Contact:
Pure Communications, Inc.
Dan Budwick, 973-271-6085
[email protected]
or
Investor Contact:
Foundation Medicine
Kimberly Brown, 617-418-2215
[email protected]

Source: Foundation Medicine, Inc.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Micware and Vissel Kobe launch joint venture for stadium digital twin
• Hongli Group regains Nasdaq minimum bid price compliance
• AvalonBay and Equity Residential shareholders approve merger